10-Q: Quarterly report which provides a continuing view of a company’s financial position

• Post author:andrewkaretas
• Post published:May 13, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading10-Q: Quarterly report which provides a continuing view of a company’s financial position

8-K: Report of unscheduled material events or corporate event

• Post author:andrewkaretas
• Post published:May 13, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading8-K: Report of unscheduled material events or corporate event

SCHEDULE 13G: SCHEDULE 13G – Description

• Post author:andrewkaretas
• Post published:May 13, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G: SCHEDULE 13G – Description

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:andrewkaretas
• Post published:May 9, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:andrewkaretas
• Post published:May 9, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description

DEFA14A: Additional proxy soliciting materials – definitive

• Post author:andrewkaretas
• Post published:April 30, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingDEFA14A: Additional proxy soliciting materials – definitive

ARS: An annual report to security holders

• Post author:andrewkaretas
• Post published:April 30, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingARS: An annual report to security holders

DEF 14A: Official notification to shareholders of matters to be brought to a vote (“Proxy”)

• Post author:andrewkaretas
• Post published:April 30, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingDEF 14A: Official notification to shareholders of matters to be brought to a vote (“Proxy”)

4: Statement of changes in beneficial ownership of securities

• Post author:andrewkaretas
• Post published:April 23, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading4: Statement of changes in beneficial ownership of securities

144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

• Post author:andrewkaretas
• Post published:April 21, 2025
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing